A controlled-release oral opioid supports S. aureus survival in injection drug preparation equipment and may increase bacteremia and endocarditis risk
Katherine J Kasper, Iswarya Manoharan, Brian Hallam, Charlotte E Coleman, Sharon L Koivu, Matthew A Weir, John K McCormick, Michael S Silverman, Katherine J Kasper, Iswarya Manoharan, Brian Hallam, Charlotte E Coleman, Sharon L Koivu, Matthew A Weir, John K McCormick, Michael S Silverman
Abstract
Background: Injection drug use-associated endocarditis (IDUaIE) incidence in Ontario has recently been associated with hydromorphone prescribing rates. Staphylococcus aureus causes the majority of cases of IDUaIE in Ontario and across North America. Hydromorphone controlled-release (Hydromorphone-CR) requires a complex technique for injection and therefore provides multiple opportunities for contamination. Hydromorphone-CR contains several excipients, which could enhance staphylococcal survival and increase risk of contaminating the injectate.
Methods: Used injection drug preparation equipment (cookers/filters) was collected from persons who inject drugs (PWID), rinsed with water, and plated on Mannitol salt agar. Bacterial isolates from bacteremic PWID were used to assess the survival of S. aureus and Streptococcus pyogenes on cookers/filters with Hydromorphone-CR, hydromorphone immediate-release (Hydromorphone-IR) or oxycodone controlled-release (Oxycodone-CR). The solutions spiked with S. aureus were heated and the remaining viable bacteria enumerated.
Results: S. aureus was detected in 12/87 (14%, 95%CI 8-23%) cookers/filters samples used for injection of Hydromorphone-CR. Hydromorphone-CR was the only opioid associated with greater survival of methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) on cookers/filters when compared to sterile water vehicle control. There was a ~2 log reduction in the number of S. aureus that survived when cookers/filters were heated.
Conclusion: 14% of all cookers/filters used in the preparation of Hydromorphone-CR were contaminated with S. aureus. Hydromorphone-CR prolongs the survival of MRSA and MSSA in cookers/filters. Heating cookers/filters may be a harm-reduction strategy.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
- Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis: challenges and perspectives. Lancet. 2012;379: 965–975. 10.1016/S0140-6736(11)60755-1(11)60755-1
- Rodger L, Glockler-Lauf SD, Shojaei E, Sherazi A, Hallam B, Koivu S, et al. Clinical Characteristics and Factors Associated With Mortality in First-Episode Infective Endocarditis Among Persons Who Inject Drugs. JAMA Netw Open. American Medical Association; 2018;1: e185220 10.1001/jamanetworkopen.2018.5220
- Schranz AJ, Fleischauer A, Chu VH, Wu L-T, Rosen DL. Trends in Drug Use–Associated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017. Ann Intern Med. 2019;170: 31 10.7326/M18-2124
- Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova NN. Trends in Infective Endocarditis in California and New York State, 1998–2013. JAMA. 2017;317: 1652 10.1001/jama.2017.4287
- Murdoch DR. Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21st Century. Arch Intern Med. 2009;169: 463 10.1001/archinternmed.2008.603
- Wilson LE, Thomas DL, Astemborski J, Freedman TL, Vlahov D. Prospective Study of Infective Endocarditis among Injection Drug Users. J Infect Dis. 2002;185: 1761–1766. 10.1086/340827
- Jain V, Yang M-H, Kovacicova-Lezcano G, Juhle LS, Bolger AF, Winston LG. Infective endocarditis in an urban medical center: Association of individual drugs with valvular involvement. J Infect. 2008;57: 132–138. 10.1016/j.jinf.2008.05.008
- Pulvirenti JJ, Kerns E, Benson C, Lisowski J, Demarais P, Weinstein RA. Infective Endocarditis in Injection Drug Users: Importance of Human Immunodeficiency Virus Serostatus and Degree of Immunosuppression. Clin Infect Dis. 1996;22: 40–45. 10.1093/clinids/22.1.40
- Bassetti S, Battegay M. Staphylococcus aureus Infections in Injection Drug Users: Risk Factors and Prevention Strategies. Infection. 2004;32: 163–169. 10.1007/s15010-004-3106-0
- Hillmer M, Wong A. Ontario Narcotics Atlas. 2016.
- Weir MA, Slater J, Jandoc R, Koivu S, Garg AX, Silverman M. The risk of infective endocarditis among people who inject drugs: a retrospective, population-based time series analysis. Can Med Assoc J. 2019;191: E93–E99. 10.1503/cmaj.180694
- Purdue Pharma. Product Monograph: HYDROMORPH CONTIN [Internet]. 2015 [cited 14 Nov 2017]. Available:
- Roy É, Arruda N, Bruneau J, Jutras-Aswad D. Epidemiology of Injection Drug Use. Can J Psychiatry. 2016;61: 136–144. 10.1177/0706743716632503
- Ball LJ, Venner C, Tirona RG, Arts E, Gupta K, Wiener JC, et al. Heating Injection Drug Preparation Equipment Used for Opioid Injection May Reduce HIV Transmission Associated With Sharing Equipment. JAIDS J Acquir Immune Defic Syndr. 2019;81: e127–e134. 10.1097/QAI.0000000000002063
- Ball LJ, Puka K, Speechley M, Wong R, Hallam B, Wiener JC, et al. Sharing of Injection Drug Preparation Equipment Is Associated With HIV Infection. JAIDS J Acquir Immune Defic Syndr. 2019;81: e99–e103. 10.1097/QAI.0000000000002062
- Performance Standards for Antimicrobial susceptibility testing. [Internet]. [cited 5 Dec 2017]. Available:
- Oxoid Antimicrobial Susceptibility Test Discs [Internet]. [cited 5 Dec 2017]. Available:
- Hryniewicz MM, Garbacz K. Borderline oxacillin-resistant Staphylococcus aureus (BORSA)–a more common problem than expected? J Med Microbiol. 2017;66: 1367–1373. 10.1099/jmm.0.000585
- Purdue Pharma. Prescribing Information, Including Patient Medication Information: DILAUDID [Internet]. [cited 14 Nov 2017]. Available:
- Purdue Pharma. Package Insert: OXYCONTIN [Internet]. [cited 14 Nov 2017]. Available:
- Smith HS. Enteral Controlled-Release Opioid Delivery Systems. Pain Med. John Wiley & Sons, Ltd (10.1111); 2009;10: S30–S38. 10.1111/j.1526-4637.2009.00597.x
- Gordon RJ, Lowy FD. Bacterial Infections in Drug Users. N Engl J Med. 2005;353: 1945–1954. 10.1056/NEJMra042823
- Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk Factors for Skin and Soft‐Tissue Abscesses among Injection Drug Users: A Case‐Control Study. Clin Infect Dis. 2001;33: 35–40. 10.1086/320879
- Richmond R. London doctors? simple strategy may stem a deadly toll | The London Free Press. In: The London Free Press [Internet]. 2017 [cited 16 Nov 2017]. Available:
- Tookes H, Diaz C, Li H, Khalid R, Doblecki-Lewis S. A Cost Analysis of Hospitalizations for Infections Related to Injection Drug Use at a County Safety-Net Hospital in Miami, Florida. Paraskevis D, editor. PLoS One. 2015;10: e0129360 10.1371/journal.pone.0129360
- Jackson KA, Bohm MK, Brooks JT, Asher A, Nadle J, Bamberg WM, et al. Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs—Six Sites, 2005–2016. MMWR Morb Mortal Wkly Rep. 2018;67: 625–628. 10.15585/mmwr.mm6722a2
- Graham PL, Lin SX, Larson EL. A U.S. Population-Based Survey of Staphylococcus aureus Colonization. Ann Intern Med. 2006;144: 318 10.7326/0003-4819-144-5-200603070-00006
- Gwizdala RA, Miller M, Bhat M, Vavagiakis P, Henry C, Neaigus A, et al. Staphylococcus aureus Colonization and Infection Among Drug Users: Identification of Hidden Networks. Am J Public Health. 2011;101: 1268–1276. 10.2105/AJPH.2010.300028
- Campanella E. More than 2.5 million needles distributed in London last year | The London Free Press. In: The London Free Press [Internet]. 2015 [cited 26 Jun 2019]. Available:
- Edelman EJ, Gordon KS, Crothers K, Akgün K, Bryant KJ, Becker WC, et al. Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. JAMA Intern Med. 2019;179: 297 10.1001/jamainternmed.2018.6101
- Dublin S, Von Korff M. Prescription Opioids and Infection Risk: Research and Caution Needed. Ann Intern Med. 2018;168: 444 10.7326/M18-0001
- Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone). Pain Pract. 2008;8: 287–313. 10.1111/j.1533-2500.2008.00204.x
- Plein LM, Rittner HL. Opioids and the immune system–friend or foe. Br J Pharmacol. 2018;175: 2717–2725. 10.1111/bph.13750
- Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel EF, et al. Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases. Ann Intern Med. 2018;168: 396 10.7326/M17-1907
- Gera K, McIver KS. Laboratory Growth and Maintenance of Streptococcus pyogenes (The Group A Streptococcus, GAS) Current Protocols in Microbiology. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2013. pp. 9D.2.1–9D.2.13. 10.1002/9780471729259.mc09d02s30
- Missiakas DM, Schneewind O. Growth and Laboratory Maintenance of Staphylococcus aureus Current Protocols in Microbiology. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2013. 10.1002/9780471729259.mc09c01s28
- Rudin L, Sjöström JE, Lindberg M, Philipson L. Factors affecting competence for transformation in Staphylococcus aureus. J Bacteriol. American Society for Microbiology (ASM); 1974;118: 155–64.
- Dickson C, Pham M, Nguyen V, Brubacher C, Silverman M, Khaled K, et al. Community outbreak of invasive group A streptococcus infection in Ontario, Canada. Canada Commun Dis Rep. 2018;44: 182–188. 10.14745/ccdr.v44i78a06
- Durack DT, Beeson PB, Petersdorf RG. Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits. Br J Exp Pathol. Wiley-Blackwell; 1973;54: 142–51.
- Gibson GW, Kreuser SC, Riley JM, Rosebury-Smith WS, Courtney CL, Juneau PL, et al. Development of a mouse model of induced Staphylococcus aureus infective endocarditis. Comp Med. 2007;57: 563–9.
Source: PubMed